Global Parkinsonâs Disease Treatment Market is expected to grow at a CAGR of 6.1% during the forecast period. Global Parkinsonâs Disease Treatment Market is expected to reach US$ 7.21 Bn. by 2026. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.To know about the Research Methodology :- Request Free Sample Report
Global Parkinson’s Disease Treatment Market, Dynamics:
Parkinson’s disease is the combination of progressive, degenerative neurological motor disorder, primarily affecting the dopaminergic cells of the brain. Rigidity, tremor, bradykinesia and postural instability are some of the common symptoms of Parkinson’s disease. Global Parkinson’s disease Treatment Market is segmented by drug class, patient care setting, distribution channel, and geography. Drug Class segment is sub-segmented as levodopa/carbidopa, dopamine receptor agonists, Mao-inhibitors and others. Distribution channel segment is classified as hospital pharmacies, retailer pharmacies, and online pharmacies. Hospital pharmacies segment is expected to dominate the market during the forecast period. A rising number of patient visits to the hospital due to the availability of diagnostic laboratories that is expected to fuel the segment growth. Patient care setting segment is bifurcated as hospitals and clinics. The market on the basis of geography is segmented by North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Increasing prevalence and rise in incidences of Parkinson’s disease across the developed countries are trending overall which results in the market growth. However, the availability of conventional treatment methods will restrain the market growth.Segment Analysis:
APAC is expected to register the highest growth rate in Parkinson’s disease Treatment Market during the forecast period followed by North America and Europe. The increasing number of generic drug manufacturers and rising aging population in this region will fuel the Parkinson’s disease Treatment Market in the APAC region.Research Methodology:
The research methodology used in this report contains various secondary sources including Bloomberg, Hoovers, and Factiva. Experts from top manufacturing companies along with other stakeholders have been considered. This is done to validate and collect critical information for evaluating trends related to this market during the forecast period. Top-down and bottom-up approaches have been used to estimate the global and regional size of this market. Data triangulation techniques along with other comparative analysis are also used to calculate the exact size of the Global Parkinson’s Disease Treatment Market globally.Global Parkinson’s disease Treatment Market, Key Highlights:
• Global Parkinson’s Disease Treatment Market analysis and forecast, in terms of value. • Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global Parkinson’s Disease Treatment Market • Global Parkinson’s disease Treatment Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided. • Global Parkinson’s disease Treatment Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study. • Global Parkinson’s Disease Treatment Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation. • Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled. • Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global Parkinson’s Disease Treatment Market are also profiled.Global Parkinson’s Disease Treatment Market: scope Inquire before buying
Key Players in the Global Parkinson’s Disease Treatment Market Are:
• GSK • Novartis • UCB • F. Hoffmann-La Roche AG • STADA Arzneimittel AG • Acadia • Wockhardt • Sun Pharma • Lundbeck • Valeant Pharmaceuticals • Abbvie • Impax • Boehringer Ingelheim • Teva • Merck • GlaxoSmithKline plc. • Bausch Health. • Lundbeck • Novartis AG • Dr. Reddy’s Laboratories Ltd., • F. Hoffmann-La Roche Ltd • STADA Arzneimittel AG • Orion Corporation.Key Target Audience:
• Research and Consuing Firms as well as Venture capitalists, private equity firms, and startup companies • Academic institutions • Parkinson’s disease treatment dealers and suppliers • Parkinson’s disease treatment product manufacturers • Parkinson’s disease associations • Human identification service providers • Contract research organizations (CROs) • Government BodiesAvailable Customization:
Maximize Market Research offers customization of report and scope of the report as per the specific requirement of our client.
Global Parkinson’s Disease Treatment Market
1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET DYNAMICS 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. END-USER OVERVIEW 4.1. Value Chain Analysis 4.2. Key Trends 5. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS (2019-2026) 5.1. Introduction 5.2. Levodopa/carbidopa 5.2.1. Levodopa/carbidopa Market Overview 5.2.2. Levodopa/carbidopa Market Size & Forecast 5.3. Dopamine Receptor Agonists 5.3.1. Dopamine Receptor Agonists Market Overview 5.3.2. Dopamine Receptor Agonists Market Size & Forecast 5.4. MAO-Inhibitors 5.4.1. MAO-Inhibitors Market Overview 5.4.2. MAO-Inhibitors Market Size & Forecast 5.5. COMT-inhibitors 5.5.1. COMT-inhibitors Market Overview 5.5.2. COMT-inhibitors Market Size & Forecast 5.6. Anticholinergics 5.6.1. Anticholinergics Market Overview 5.6.2. Anticholinergics Market Size & Forecast 5.7. Other Drugs 5.7.1. Other Drugs Market Overview 5.7.2. Other Drugs Market Size & Forecast 6. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2019-2026) 6.1. Introduction 6.2. Hospital Pharmacies 6.2.1. Hospital Pharmacies Market Overview 6.2.2. Hospital Pharmacies Market Size & Forecast 6.3. Retailer Pharmacies 6.3.1. Retailer Pharmacies Market Overview 6.3.2. Retailer Pharmacies Market Size & Forecast 6.4. Online Pharmacies 6.4.1. Online Pharmacies Market Overview 6.4.2. Online Pharmacies Market Size & Forecast 7. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING (2019-2026) 7.1. Introduction 7.2. Hospitals 7.2.1. Hospitals Market Overview 7.2.2. Hospitals Market Size & Forecast 7.3. Clinics 7.3.1. Clinics Market Overview 7.3.2. Clinics Market Size & Forecast 8. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY GEOGRAPHY (2019-2026) 8.1. North America Parkinson’s Disease Treatment Market 8.1.1. North America Parkinson’s Disease Treatment Market, By Drug Class 8.1.2. North America Parkinson’s Disease Treatment Market, By Distribution Channel 8.1.3. North America Parkinson’s Disease Treatment Market, By Patient Care Setting 8.1.4. North America Parkinson’s Disease Treatment Market, by Region 8.1.4.1. U.S. Parkinson’s Disease Treatment Market 8.1.4.2. Canada Parkinson’s Disease Treatment Market 8.1.4.3. Mexico Parkinson’s Disease Treatment Market 8.2. Europe Parkinson’s Disease Treatment Market 8.2.1. Europe Parkinson’s Disease Treatment Market, By Drug Class 8.2.2. Europe Parkinson’s Disease Treatment Market, By Distribution Channel 8.2.3. Europe Parkinson’s Disease Treatment Market, By Patient Care Setting 8.2.4. Europe Global Parkinson’s Disease Treatment Market, by Region 8.2.4.1. France Parkinson’s Disease Treatment Market 8.2.4.2. Germany Parkinson’s Disease Treatment Market 8.2.4.3. U.K. Parkinson’s Disease Treatment Market 8.2.4.4. Italy Parkinson’s Disease Treatment Market 8.2.4.5. Spain Parkinson’s Disease Treatment Market 8.2.4.6. Rest of Europe Parkinson’s Disease Treatment Market 8.3. Asia Pacific Parkinson’s Disease Treatment Market 8.3.1. Asia-Pacific Parkinson’s Disease Treatment Market, By Drug Class 8.3.2. Asia-Pacific Parkinson’s Disease Treatment Market, By Distribution Channel 8.3.3. Asia-Pacific Parkinson’s Disease Treatment Market, By Patient Care Setting 8.3.4. Asia-Pacific Parkinson’s Disease Treatment Market, by Region 8.3.4.1. China Parkinson’s Disease Treatment Market 8.3.4.2. Japan Parkinson’s Disease Treatment Market 8.3.4.3. India Parkinson’s Disease Treatment Market 8.3.4.4. South Korea Parkinson’s Disease Treatment Market 8.3.4.5. Rest of Asia Pacific Parkinson’s Disease Treatment Market 8.4. Middle East & Africa Parkinson’s Disease Treatment Market 8.4.1. Middle East & Africa Parkinson’s Disease Treatment Market, By Drug Class 8.4.2. Middle East & Africa Parkinson’s Disease Treatment Market, By Distribution Channel 8.4.3. Middle East & Africa Parkinson’s Disease Treatment Market, By Patient Care Setting 8.4.4. Middle East & Africa Parkinson’s Disease Treatment Market, by Region 8.4.4.1. South Africa Parkinson’s Disease Treatment Market 8.4.4.2. Rest of Middle East and Africa Parkinson’s Disease Treatment Market 8.5. Latin America Parkinson’s Disease Treatment Market 8.5.1. Latin America Parkinson’s Disease Treatment Market, By Drug Class 8.5.2. Latin America Parkinson’s Disease Treatment Market, By Distribution Channel 8.5.3. Latin America Parkinson’s Disease Treatment Market, By Patient Care Setting 8.5.4. Latin America Parkinson’s Disease Treatment Market, by Region 8.5.4.1. Brazil Parkinson’s Disease Treatment Market 8.5.4.2. Rest of Latin America Parkinson’s Disease Treatment Market 9. MARKET COMPETITION ANALYSIS 9.1 Market Share/Positioning Analysis 9.2 Key Innovators 9.3 Company Profiles 9.3.1 GSK 9.3.1.1 Overview 9.3.1.2 Products/ End-User 9.3.1.3 Strategy 9.3.1.4 Key Developments 9.3.2 Novartis 9.3.2.1 Overview 9.3.2.2 Products/ End-User 9.3.2.3 Strategy 9.3.2.4 Key Developments 9.3.3 UCB 9.3.3.1 Overview 9.3.3.2 Products/ End-User 9.3.3.3 Strategy 9.3.3.4 Key Developments 9.3.4 F. Hoffmann-La Roche AG 9.3.4.1 Overview 9.3.4.2 Products/ End-User 9.3.4.3 Strategy 9.3.4.4 Key Developments 9.3.5 STADA Arzneimittel AG 9.3.5.1 Overview 9.3.5.2 Products/ End-User 9.3.5.3 Strategy 9.3.5.4 Key Developments 9.3.6 Acadia 9.3.6.1 Overview 9.3.6.2 Products/ End-User 9.3.6.3 Strategy 9.3.6.4 Key Developments 9.3.7 Wockhardt 9.3.7.1 Overview 9.3.7.2 Products/ End-User 9.3.7.3 Strategy 9.3.7.4 Key Development 9.3.8 Sun Pharma 9.3.8.1 Overview 9.3.8.2 Products/ End-User 9.3.8.3 Strategy 9.3.8.4 Key Development 9.3.9 Lundbeck 9.3.9.1 Overview 9.3.9.2 Products/ End-User 9.3.9.3 Strategy 9.3.9.4 Key Development 9.3.10 Valeant Pharmaceuticals 9.3.10.1 Overview 9.3.10.2 Products/ End-User 9.3.10.3 Strategy 9.3.10.4 Key Development 9.3.11 Abbvie 9.3.11.1 Overview 9.3.11.2 Products/ End-User 9.3.11.3 Strategy 9.3.11.4 Key Development 9.3.12 Impax 9.3.12.1 Overview 9.3.12.2 Products/ End-User 9.3.12.3 Strategy 9.3.12.4 Key Development 9.3.13 Boehringer Ingelheim 9.3.13.1 Overview 9.3.13.2 Products/ End-User 9.3.13.3 Strategy 9.3.13.4 Key Development 9.3.14 Teva 9.3.14.1 Overview 9.3.14.2 Products/ End-User 9.3.14.3 Strategy 9.3.14.4 Key Development 9.3.15 Merck 9.3.15.1 Overview 9.3.15.2 Products/ End-User 9.3.15.3 Strategy 9.3.15.4 Key Development 9.3.16 GlaxoSmithKline plc. 9.3.17 Bausch Health. 9.3.18 Lundbeck 9.3.19 Novartis AG 9.3.20 Dr. Reddy’s Laboratories Ltd., 9.3.21 F. Hoffmann-La Roche Ltd 9.3.22 STADA Arzneimittel AG 9.3.23 Orion Corporation.